PRTC vs. OXB, ERGO, SLN, HZD, AVCT, VRP, FARN, ARIX, CIR, and BVXP
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
PureTech Health vs. Its Competitors
PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
PureTech Health currently has a consensus target price of GBX 455, indicating a potential upside of 239.05%. Oxford Biomedica has a consensus target price of GBX 558, indicating a potential downside of 13.89%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.
Oxford Biomedica has a net margin of -145.98% compared to PureTech Health's net margin of -17,620.94%. PureTech Health's return on equity of -21.15% beat Oxford Biomedica's return on equity.
53.1% of PureTech Health shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 13.4% of PureTech Health shares are held by insiders. Comparatively, 41.9% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Oxford Biomedica had 4 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Oxford Biomedica and 0 mentions for PureTech Health. Oxford Biomedica's average media sentiment score of 0.10 beat PureTech Health's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.
PureTech Health has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Summary
PureTech Health and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 10/9/2025 by MarketBeat.com Staff
